Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Trump Buys SpaceX Shares After Record IPO 
Add as a preferred source on Google
WALTHAM, Mass., May 01, 2018 -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it will be participating in the 3rd annual Disruptive Growth & Healthcare Conference in New York City on May 8-9, 2018 sponsored by RHK Capital and ReedSmith. The conference offers an opportunity to discover life science companies focusing on unmet medical needs with disruptive technologies and business models. Those interested in attending the conference should visit http://disruptnyc.com/ for more information.
Shai Gozani, M.D., Ph.D., President and CEO of NeuroMetrix, Inc. will participate in a Pain Management Panel Discussion at 3:00 PM EDT on May 8. At 4:40 PM EDT on May 8 Dr. Gozani will present a business update and commentary on Quell®, the company’s a wearable device for management of chronic pain. A live webcast of the 4:40 PM EDT presentation will be available on NeuroMetrix’ investor relations page.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell®, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more
information, please visit NeuroMetrix.com.
About RHK Capital:
Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.
About ReedSmith:
Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. Their long-standing relationships and international outlook make them the go-to partner for speedy resolution of complex transactions, disputes and regulatory matters.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
[email protected]
Source: NeuroMetrix, Inc.
